Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Leon Perel

Pain Medicine Las Vegas, NV Medical Doctor

NPI 1871754572 CMS profile 357988

6990 Smoke Ranch Rd, Las Vegas, NV 89128

Open in the dashboard

General payments

$2,876

74 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leon Perel of Las Vegas, NV is reported in the CMS Open Payments database as having received $2,876 across 74 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 54th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $929 26
2024 General $87 4
2023 General $53 3
2022 General $211 14
2021 General $58 4
2020 General $284 10
2019 General $1,255 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leon Perel
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Leon Perel were reported at $929. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Leon Perel Pain Medicine median Middle half National median
2019 $1,255 $498 $126–$1,682 $163
2020 $284 $284 $80–$910 $114
2021 $58 $399 $112–$1,219 $132
2022 $211 $455 $137–$1,484 $149
2023 $53 $484 $128–$1,495 $160
2024 $87 $498 $131–$1,540 $164
2025 $929 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $1,717 57 payments
  2. Vertiflex, Inc. $855 5 payments
  3. Boston Scientific Corporation $130 2 payments
  4. Curonix LLC $75 4 payments
  5. Orexo US, Inc. $72 4 payments
  6. Biodelivery Sciences International, Inc. $27 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,525 71 payments
  2. Travel and Lodging $702 2 payments
  3. Consulting Fee $650 1 payment
Products named General payments · program years 2019–2025
  1. Superion ISS $855 5 payments
  2. PROCLAIM Structural Heart $729 4 payments
  3. Proclaim Family of SCS IPGs $476 11 payments
  4. GENERAL PAIN MANAGEMENT $117 1 payment
  5. PROCLAIM Neuromodulation $90 5 payments
  6. PROCLAIM Structural Heart $79 8 payments
  7. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $75 4 payments
  8. Octrode SCS Leads $70 5 payments
  9. OCTRODE $65 6 payments
  10. Zubsolv $53 3 payments
  11. Other $247 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,120

Median for Pain Management: 951

Drug cost

$18,212

Median for Pain Management: $26,034

Branded share of claims

16.1%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 277 $2,716
Buprenorphine Generic 12 $1,887
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 63 $1,872
Lidocaine Generic 16 $1,652
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 83 $1,606
Pregabalin Generic 129 $1,580
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 13 $1,083
Methocarbamol Generic 120 $1,055
Diclofenac Sodium Generic 92 $997
Cephalexin Generic 58 $624

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$120,668

Of which drugs: $34

Medicare patients

309

Average age 72

Services billed

1,644

197 women, 112 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 35%
Depression 32%
Chronic kidney disease 29%
Ischemic heart disease 25%
COPD 20%
Osteoporosis 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 19 210 $19

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

74 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record